JPRN-UMIN000006120招募中未知
A randomised clinical trial of docetaxel and estrogen in patients with castration resistant prostate cancer - Docetaxel and Estrogen in CRPC
Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences0 个研究点目标入组 80 人开始时间: 2011年9月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1)Patients who received cytotxic-chemotherapy prior to this trial. 2)Patients who received estrogen therapy prior to this trial. 3)Patients who received radiation therapy to primary cancer site within 3 monthsprior to this trial. 4)Patients who diagnosed pulmonary fibrosis or interstitial pneumonitis. 5)Patients who have a history of acute myocardial infarction within 6 months. 6)Severe cormobidity (DM, heart disease, liver dysfunction etc.)
研究者
相似试验
已完成
2 期
Randomised Phase II study of combined Docetaxel and Nedaplatin versus Docetaxel alone chemotherapy in advanced or recurrent esophageal cancerAdvanced or recurrent esophageal cancerJPRN-UMIN000005877Toho University43
进行中（未招募）
1 期
A randomised phase II/III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolone plus Zoledronic Acid plus Strontium-89 in Hormone Refractory Prostate Cancer metastatic to bone. - TRAPEZE: phase II/III efficacy and safety clinical trial in Hormone Refractory Prostate CancerHormone refractory Prostate Cancer (HRPC)EUCTR2004-002295-41-GBThe University of Birmingham757
已完成
不适用
Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancerunresectable advanced gastric cancerJPRN-C000000080Fourth Department of Internal Medicine, Sapporo Medical University40
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270